{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:34:21Z","timestamp":1791146061991,"version":"4.1.0"},"reference-count":73,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T00:00:00Z","timestamp":1415577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Despite the significant advances in modern chemotherapy, it remains challenging to treat adult patients with acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). The relapse rate remains high, and the outcome at the time of relapse is dismal. Antibody\u2010based therapies have demonstrated promising results in this patient group. Variable mechanisms have been applied to target surface antigens (<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 [also termed <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>4A1], <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>22, <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>52 and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19) that are commonly expressed on malignant leukaemia cells. In this review, we will focus on the clinical application of such therapies in adult <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, including the naked antibodies: Rituximab, Ofatumumab, Epratuzumab and Alemtuzumab; the immunotoxins: <jats:styled-content style=\"fixed-case\">BL<\/jats:styled-content>22 and Combotox; the immunoconjugates: inotuzumab and <jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content> 3419; as well as the Bi\u2010specific T cell engaging (Bi<jats:styled-content style=\"fixed-case\">TE<\/jats:styled-content>)\u2010specific antibody, Blinatumomab.<\/jats:p>","DOI":"10.1111\/bjh.13205","type":"journal-article","created":{"date-parts":[[2014,11,10]],"date-time":"2014-11-10T11:30:16Z","timestamp":1415619016000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Current status of antibody therapy in <scp>ALL<\/scp>"],"prefix":"10.1111","volume":"168","author":[{"given":"Jing","family":"Ai","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders Taussig Cancer Institute Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders Taussig Cancer Institute Cleveland Clinic Cleveland OH USA"},{"name":"Cleveland Clinic Lerner College of Medicine Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,10]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.131"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V114.22.3094.3094","article-title":"Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine\/cytarabine for relapsed refractory acute lymphocytic leukemia","volume":"114","author":"Advani A.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12778"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22209"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0485"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1437.1437","article-title":"A first\u2010in\u2010human phase 1 study of the antibody\u2010drug conjugate SGN\u2010CD19A in relapsed or refractory B\u2010lineage acute leukemia and highly aggressive lymphoma","volume":"122","author":"Borate U.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0298-z"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156750c"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3613"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12183"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701647879"},{"key":"e_1_2_9_16_1","first-page":"2612","article-title":"Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22\u2010positive acute lymphoblastic leukemia","volume":"120","author":"DeAngelo D.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_17_1","first-page":"3906","article-title":"Weekly inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory CD22\u2010positive acute lymphoblastic leukemia (ALL)","volume":"122","author":"DeAngelo D.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404866"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164129"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5856"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.239"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181bdf211"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"747a","DOI":"10.1182\/blood.V104.11.2732.2732","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL)","volume":"104","author":"Hoelzer D.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B\u2010lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer D.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x"},{"key":"e_1_2_9_28_1","first-page":"2664","article-title":"Phase II study of the hyper\u2010CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD\u201020 positive acute lymphoblastic leukemia (ALL)","volume":"122","author":"Jabbour E.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_29_1","first-page":"1432","article-title":"Inotuzumab ozogamicin in combination with low\u2010intensity chemotherapy (mini\u2010hyper\u2010CVD) as frontline therapy for older patients (\u226560\u00a0years) with acute lymphoblastic leukemia (ALL)","volume":"122","author":"Jain N.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2184"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6768"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0487"},{"key":"e_1_2_9_34_1","first-page":"215b","article-title":"Update of efficacy and safety of gemtuzumab ozogamicin (Mylotarg (R), CMA\u2010676) in patients >=60\u00a0years of age with acute myeloid leukemia in first relapse","volume":"98","author":"Larson R.A.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225474"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.09.019"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.1.18348"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08251.x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902943077"},{"key":"e_1_2_9_42_1","first-page":"671","article-title":"Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory\u2010relapsed acute lymphocytic leukemia (ALL)","volume":"120","author":"Obrien S.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000139648"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V112.11.1907.1907","article-title":"Implications for the use of monoclonal antibodies in future adult ALL trials: analysis of antigen expression in 505 B\u2010lineage (B\u2010Lin) ALL patients (pts) on the MRC UKALLXII\/ECOG2993 intergroup trial","volume":"112","author":"Paietta E.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1121"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.539557"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-012-0120-7"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.823493"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3528"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1414"},{"key":"e_1_2_9_51_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V118.21.573.573","article-title":"Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children's Oncology Group (COG) Study ADVL04P2","volume":"118","author":"Raetz E.A.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0580"},{"key":"e_1_2_9_54_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.V116.21.858.858","article-title":"Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt \u2010 like leukemia\/lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002","volume":"116","author":"Rizzieri D.A.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_9_56_1","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti\u2010CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Salvatore G.","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08762.x"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_9_59_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V114.22.838.838","article-title":"Alemtuzumab can be incorporated into front\u2010line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102)","volume":"114","author":"Stock W.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.005"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21901"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_2_9_68_1","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2012.30.15_suppl.6500","article-title":"Effect of anti\u2010CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed\/refractory B\u2010precursor ALL","volume":"30","author":"Topp M.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.206"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0255"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.05.006"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2980"},{"key":"e_1_2_9_73_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.V118.21.248.248","article-title":"A novel anti\u2010CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL)","volume":"118","author":"Wayne A.S.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1204523109"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:13:29Z","timestamp":1696353209000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,10]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/bjh.13205"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13205","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,10]]},"assertion":[{"value":"2014-11-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}